Parkinson's disease gene therapy: Success by design meets failure by efficacy

Molecular Therapy

Volumn 22, Issue 3, 2014, Pages 487-497

  Bartus, Raymond T ^a,b   Weinberg, Marc S ^c   Samulski, R Jude ^c  

^a Ceregene Inc   (United States)

^b RTBioconsultants Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LENTIVIRUS VECTOR; NEURTURIN; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

CLINICAL EFFECTIVENESS; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; HUMAN; MOTOR DYSFUNCTION; MOTOR NERVE CONDUCTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT SELECTION; REVIEW; TREATMENT OUTCOME;

ANIMALIA;

ANIMALS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PARKINSON DISEASE; RESEARCH DESIGN;

EID: 84895442417     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.281     Document Type: Review

References (91)

1. Olanow, CW, Stern, MB and Sethi, K (2009). The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72 (suppl. 4): S1-136.
2. Bonnet, AM, Jutras, MF, Czernecki, V, Corvol, JC and Vidailhet, M (2012). Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis 2012: 198316.
3. Braak, H, Del Tredici, K, Rüb, U, de Vos, RA, Jansen Steur, EN and Braak, E (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
4. Parkinson's Disease Foundation (2013). Statistics on Parkinson's. http://www.pdf.org/ en/parkinson-statistics.
5. Bartus, RT (2012). Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest. Neurobiol Dis 48: 153-178.
6. Szerlip, NJ, Walbridge, S, Yang, L, Morrison, PF, Degen, JW, Jarrell, ST et al. (2007). Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg 107: 560-567.
7. Fiandaca, MS, Varenika, V, Eberling, J, McKnight, T, Bringas, J, Pivirotto, P et al. (2009). Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 47 (suppl. 2): T27-T35.
8. Bankiewicz, KS, Eberling, JL, Kohutnicka, M, Jagust, W, Pivirotto, P, Bringas, J et al. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using prodrug approach. Exp Neurol 164: 2-14.
9. Luo, J, Kaplitt, MG, Fitzsimons, HL, Zuzga, DS, Liu, Y, Oshinsky, ML et al. (2002). Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298: 425-429.
10. Emborg, ME, Carbon, M, Holden, JE, During, MJ, Ma, Y, Tang, C et al. (2007). Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27: 501-509.
11. Jarraya, B, Boulet, S, Ralph, GS, Jan, C, Bonvento, G, Azzouz, M et al. (2009). Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1: 2ra4.
12. Aron, L and Klein, R (2011). Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 34: 88-100.
13. Peterson, AL and Nutt, JG (2008). Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5: 270-280.
14. Kells, AP, Eberling, J, Su, X, Pivirotto, P, Bringas, J, Hadaczek, P et al. (2010). Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 30: 9567-9577.
15. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105.
16. LeWitt, PA, Rezai, AR, Leehey, MA, Ojemann, SG, Flaherty, AW, Eskandar, EN et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10: 309-319.
17. Coune, PG, Schneider, BL and Aebischer, P (2012). Parkinson's disease: gene therapies. Cold Spring Harb Perspect Med 2: a009431.
18. Su, X, Kells, AP, Huang, EJ, Lee, HS, Hadaczek, P, Beyer, J et al. (2009). Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20: 1627-1640.
19. Pierce, G (2003). A phase 1 open-label safety study of intrastriatal infusion of adeno-associated virus encoding human aromatic L-amino acid decarboxylase (AAVhAADC- 2) in subjects with advanced parkinson's disease [AAV-hAADC-2-003]. NIH Recombinant DNA Advisory Committee-Appendix M.
20. Avigen (2005). Genzyme Acquires Significant Portion of Avigen's Gene Therapy Technology. 21 December 2005 Press Release.
21. Mittermeyer, G, Christine, CW, Rosenbluth, KH, Baker, SL, Starr, P, Larson, P et al. (2012). Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 23: 377-381.
22. Christine, CW, Starr, PA, Larson, PS, Eberling, JL, Jagust, WJ, Hawkins, RA et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73: 1662-1669.
23. Bankiewicz, KS, Forsayeth, J, Eberling, JL, Sanchez-Pernaute, R, Pivirotto, P, Bringas, J et al. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14: 564-570.
24. Forsayeth, JR, Eberling, JL, Sanftner, LM, Zhen, Z, Pivirotto, P, Bringas, J et al. (2006). A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 14: 571-577.
25. Hadaczek, P, Eberling, JL, Pivirotto, P, Bringas, J, Forsayeth, J and Bankiewicz, KS (2010). Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18: 1458-1461.
26. Bjorklund, T and Kordower, JH (2010). Gene therapy for Parkinson's disease. Mov Disord 25 (suppl. 1): S161-S173.
27. Herpich, N (2013). Novel partnership between academia and industry drives forward gene therapy approach to treat Parkinson's. FoxFeed Blog: http://www.michaeljfox. org/foundation/news-detail.php?novel-partnership- between-academia-and-industrydrives- forward-gene-therapy-approach-to-treat- parkinson.
28. Muramatsu, S, Fujimoto, K, Kato, S, Mizukami, H, Asari, S, Ikeguchi, K et al. (2010). A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18: 1731-1735.
29. Denyer, R and Douglas, MR (2012). Gene therapy for Parkinson's disease. Parkinsons Dis 2012: 757305.
30. Hwu, WL, Muramatsu, S, Tseng, SH, Tzen, KY, Lee, NC, Chien, YH et al. (2012). Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 4: 134ra61.
31. Markakis, EA, Vives, KP, Bober, J, Leichtle, S, Leranth, C, Beecham, J et al. (2010). Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 18: 588-593.
32. Weinberg, MS, Samulski, RJ and McCown, TJ (2013). Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 69: 82-88.
33. Harding, TC, Dickinson, PJ, Roberts, BN, Yendluri, S, Gonzalez-Edick, M, Lecouteur, RA et al. (2006). Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors. Hum Gene Ther 17: 807-820.
34. Klein, RL, Dayton, RD, Tatom, JB, Henderson, KM and Henning, PP (2008). AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 16: 89-96.
35. Bankiewicz, KS, Daadi, M, Pivirotto, P, Bringas, J, Sanftner, L, Cunningham, J et al. (2006). Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol 197: 363-372.
36. Bartus, RT, Brown, L, Wilson, A, Kruegel, B, Siffert, J, Johnson, EM Jr et al. (2011). Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 44: 38-52.
37. Bartus, R, Baumann, TL, Siffert, J, Herzog, CD, Alterman, R, Boulis, N et al (2013). Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson's patients. Neurology, 80: 1698-1702.
38. Marks, WJ Jr, Bartus, RT, Siffert, J, Davis, CS, Lozano, A, Boulis, N et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9: 1164-1172.
39. Bartus, R (2013). CERE-120 (AAV-neurturin) for the Treatment of Parkinson's Disease: Experience from 4 Clinical Trials and Human Autopsy Data. American Society of Gene and Cell Therapy 16th Annual Meeting: Salt Palace Convention Center in Salt Lake City, Utah, USA..
40. Marks, WJ Jr, Ostrem, JL, Verhagen, L, Starr, PA, Larson, PS, Bakay, RA et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7: 400-408.
41. Bartus, RT, Baumann, TL, Brown, L, Kruegel, BR, Ostrove, JM and Herzog, CD (2013). Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol Aging 34: 35-61.
42. Herzog, CD, Brown, L, Kruegel, BR, Wilson, A, Tansey, MG, Gage, FH et al. (2013). Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis 58: 38-48.
43. Herzog, CD, Brown, L, Chu, Y, Baumann, T, Kordower, JH, Bartus, RT. Robust, stable, targeted, long-term neurturin expression and enhanced tyosine hyroxylase labeling in Parkinson's disease brain 4 years following delivery of CERE-120 (AAV2-neurturin) to the human putamen. Society for Neuroscience: New Orleans, LA, 2012.
44. Bartus, RT, Herzog, CD, Chu, Y, Wilson, A, Brown, L, Siffert, J et al. (2011). Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 26: 27-36.
45. Kordower, JH, Herzog, CD, Dass, B, Bakay, RA, Stansell, J 3rd, Gasmi, M et al. (2006). Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60: 706-715.
46. Herzog, CD, Dass, B, Holden, JE, Stansell, J 3rd, Gasmi, M, Tuszynski, MH et al. (2007). Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22: 1124-1132.
47. Decressac, M, Ulusoy, A, Mattsson, B, Georgievska, B, Romero-Ramos, M, Kirik, D et al. (2011). GDNF fails to exert neuroprotection in a rat a-synuclein model of Parkinson's disease. Brain 134(Pt 8): 2302-2311.
48. Decressac, M, Kadkhodaei, B, Mattsson, B, Laguna, A, Perlmann, T and Björklund, A (2012). a-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 4: 163ra156.
49. Lo Bianco, C, Déglon, N, Pralong, W and Aebischer, P (2004). Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol Dis 17: 283-289.
50. Akerud, P, Alberch, J, Eketjäll, S, Wagner, J and Arenas, E (1999). Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem 73: 70-78.
51. Rosenblad, C, Kirik, D, Devaux, B, Moffat, B, Phillips, HS and Björklund, A (1999). Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11: 1554-1566.
52. Gasmi, M, Brandon, EP, Herzog, CD, Wilson, A, Bishop, KM, Hofer, EK et al. (2007). AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: longterm efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 27: 67-76.
53. Ceregene, I (2013). Ceregene reports data from Parkinson's disease phase 2b study. http://www.ceregene.com/press-041913.asp.
54. Eriksdotter Jönhagen, M, Nordberg, A, Amberla, K, Bäckman, L, Ebendal, T, Meyerson, B et al. (1998). Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9: 246-257.
55. Nauta, HJ, Wehman, JC, Koliatsos, VE, Terrell, MA and Chung, K (1999). Intraventricular infusion of nerve growth factor as the cause of sympathetic fiber sprouting in sensory ganglia. J Neurosurg 91: 447-453.
56. Nutt, JG, Burchiel, KJ, Comella, CL, Jankovic, J, Lang, AE, Laws, ER Jr et al.; ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73.
57. Olanow, CW, Goetz, CG, Kordower, JH, Stoessl, AJ, Sossi, V, Brin, MF et al. (2003). A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54: 403-414.
58. Lang, AE, Gill, S, Patel, NK, Lozano, A, Nutt, JG, Penn, R et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466.
59. Hovland, DN Jr, Boyd, RB, Butt, MT, Engelhardt, JA, Moxness, MS, Ma, MH et al. (2007). Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 35: 1013-1029.
60. Herzog, CD, Dass, B, Gasmi, M, Bakay, R, Stansell, JE, Tuszynski, M et al. (2008). Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther 16: 1737-1744.
61. Herzog, CD, Brown, L, Gammon, D, Kruegel, B, Lin, R, Wilson, A et al. (2009). Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 64: 602-12; discussion 612.
62. Herzog, CD, Bishop, K, Brown, L, Wilson, A, Kordower, JH and Bartus, RT (2011). Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically-active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv and Transl Res 1: 361-382.
63. Grieger, JC and Samulski, RJ (2012). Adeno-associated virus vectorology, manufacturing, and clinical applications. Meth Enzymol 507: 229-254.
64. Xiao, X, Li, J and Samulski, RJ (1998). Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232.
65. Aslanidi, G, Lamb, K and Zolotukhin, S (2009). An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci USA 106: 5059-5064.
66. Clément, N, Knop, DR and Byrne, BJ (2009). Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther 20: 796-806.
67. Lang, AE and Obeso, JA (2004). Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 3: 309-316.
68. Zhu, S, Stavrovskaya, IG, Drozda, M, Kim, BY, Ona, V, Li, M et al. (2002). Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78.
69. Gordon, PH, Moore, DH, Miller, RG, Florence, JM, Verheijde, JL, Doorish, C et al.; Western ALS Study Group. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6: 1045-1053.
70. O'Reilly, M, Kohn, DB, Bartlett, J, Benson, J, Brooks, PJ, Byrne, BJ et al. (2013). Gene therapy for rare diseases: summary of a national institutes of health workshop, september 13, 2012. Hum Gene Ther 24: 355-362.
71. Kordower, JH, Olanow, CW, Dodiya, HB, Chu, Y, Beach, TG, Adler, CH et al. (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136(Pt 8): 2419-2431.
72. Kang, JH, Irwin, DJ, Chen-Plotkin, AS, Siderowf, A, Caspell, C, Coffey, CS et al. (2013). Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-Synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. doi:10.1001/jamaneurol.2013. 3861.
73. Chung, CY, Koprich, JB, Siddiqi, H and Isacson, O (2009). Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 29: 3365-3373.
74. Kirik, D, Rosenblad, C, Burger, C, Lundberg, C, Johansen, TE, Muzyczka, N et al. (2002). Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22: 2780-2791.
75. Lo Bianco, C, Ridet, JL, Schneider, BL, Deglon, N and Aebischer, P (2002). alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 99: 10813-10818.
76. Scott, DA, Tabarean, I, Tang, Y, Cartier, A, Masliah, E and Roy, S (2010). A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30: 8083-8095.
77. Centocor Inc, H (1996). Centocor Inc History. vol. 14. St. James Press: International Directory of Company Histories.
78. McCloskey, RV, Straube, RC, Sanders, C, Smith, SM and Smith, CR (1994). Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121: 1-5.
79. Marks, L (2012). The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin. MAbs 4: 403-412.
80. An, Z (2009). Therapeutic Monoclonal Antibodies: From bench to clinic: Hoboken, New Jersey.
81. Jones, D (2011). The long march of antisense. Nat Rev Drug Discov 10: 401-402.
82. Mount, JD, Herzog, RW, Tillson, DM, Goodman, SA, Robinson, N, McCleland, ML et al. (2002). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99: 2670-2676.
83. Wang, L, Nichols, TC, Read, MS, Bellinger, DA and Verma, IM (2000). Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 1: 154-158.
84. Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW, Arruda, VR et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972.
85. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
86. McCarty, DM, Fu, H, Monahan, PE, Toulson, CE, Naik, P and Samulski, RJ (2003). Adenoassociated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112-2118.
87. Wu, Z, Sun, J, Zhang, T, Yin, C, Yin, F, Van Dyke, T et al. (2008). Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 16: 280-289.
88. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
89. Monahan, PE, Walsh, C, Powell, J, Gomperts, E, Samulski, RJ, Mcphee, S (2013). A phase 1/2 open-label trial of an adeno-associated virus (AAV) serotype 8 factor IX gene therapy (AskBio009) in adults with hemophilia B. Haemophilia 19: 468-469.
90. Lonser, RR (2009). A phase 1 open-label dose escalation safety study of convectionenhanced delivery (CED) of adeno-associated virus encoding glial cell line-derived neurotrophic factor (AAV2-GDNF) in subjects with advanced Parkinson's disease. Recombinant DNA Advisory Committee Protocol 0901-962.
91. Palfi, S, Gurruchaga, JM, Ralph, GS, Lepetit, H, Lavisse, S, Buttery, PC et al. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy of Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. The Lancet, http://dx.doi.org/10.1016/S0140-6736(13)61939-X.